David A. Scheinberg
Memorial Sloan Kettering Cancer Center · 496 works · 26,225 citations · h-index 81
Top works
- Central Challenges Facing the National Clinical Research Enterprise
- Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
- United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
- Tumor Imaging with Radioactive Metal Chelates Conjugated to Monoclonal Antibodies
- Tumor Therapy with Targeted Atomic Nanogenerators
- Radioimmunotherapy with alpha-emitting nuclides
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures
- Targeted α particle immunotherapy for myeloid leukemia
- A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.
- Arsenic Trioxide and Melarsoprol Induce Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-RAR Independent Manner
- Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia
- Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes
- Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression
- Acute myeloid leukaemia
- An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
- Infection with Human T-Cell Leukemia Virus Type I in Patients with Leukemia
- A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.
- Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization